Unlock a deeper view of
Unlock a deeper view of
Unlock a deeper view of
Cardiovascular Risk
Cardiovascular Risk
Cardiovascular Risk
Supporting providers in interpreting cardiovascular risk with greater depth and structure,
Supporting providers in interpreting cardiovascular risk with greater depth and structure,
Supporting providers in interpreting cardiovascular risk with greater depth and structure,
CLINICAL PROOF
CLINICAL PROOF
Expanding the boundaries of
Clinical Visibility
Expanding the boundaries of
Clinical Visibility
Expanding the boundaries of
Clinical Visibility
This is not a failure of medicine, but a limit of what current workflows can reveal.
The goal is to extend clinical visibility, so providers can see beyond where it traditionally stops.
This is not a failure of medicine, but a limit of what current workflows can reveal. The goal is to extend clinical visibility, so doctors can see beyond where it traditionally stops.
This is not a failure of medicine, but a limit of what current workflows can reveal.
The goal is to extend clinical visibility, so providers can see beyond where it traditionally stops.
Case Pattern 1
Case Pattern 2
Case Pattern 3
Inflammation Source Misidentified
What Standard Care Saw ?
CRP elevated at 8× clinical threshold. Interpretation: systemic inflammation.
Plan: anti-inflammatory escalation
What Vizzhy Revealed ?
Inflammatory gene expression at the 43rd percentile, essentially normal at the level of immune authorization.
The genome was not supporting the kind of inflammatory pattern the surface marker suggested.
The liver appeared to be producing acute phase proteins driven by a different axis, not an immune-cell-dominant inflammatory state.
What Changed ?
Drug escalation would have targeted the wrong process. The intervention shifted toward the
actual upstream axis. Drug class logic, monitoring cadence, and follow-up strategy changed.
Case Pattern 1
Inflammation Source Misidentified
Case Pattern 2
Silent Hypercoagulable State
Case Pattern 3
Guideline Drug Contraindicated for This Biology
What Standard Care Saw ?
CRP elevated at 8× clinical threshold. Interpretation: systemic inflammation.
Plan: anti-inflammatory escalation
What Vizzhy Revealed ?
Inflammatory gene expression at the 43rd percentile, essentially normal at the level of immune authorization.
The genome was not supporting the kind of inflammatory pattern the surface marker suggested.
The liver appeared to be producing acute phase proteins driven by a different axis, not an immune-cell-dominant inflammatory state.
What Changed ?
Drug escalation would have targeted the wrong process. The intervention shifted toward the actual upstream axis.
Drug class logic, monitoring cadence, and follow-up strategy changed.
If the biology is different, the care should not stop at “same lesion, same logic.” What looks identical in anatomy can be entirely non-equivalent in biology.
If the biology is different, the care should not stop at “same lesion, same logic.” What looks identical in anatomy can be entirely non-equivalent in biology.
If the biology is different, the care should not stop at “same lesion, same logic.” What looks identical in anatomy can be entirely non-equivalent in biology.
Medicines assume patients behave like averages.
Medicines assume patients behave like averages.
Medicines assume patients behave like averages.
Biology does not.
Biology does not.
Biology does not.
What You Get with Vizzhy
What You Get with Vizzhy
Deeper Case Review
Deeper Case Review
Deeper Case Review
Richer cardiovascular interpretation across biological layers
Richer cardiovascular interpretation across biological layers
Structured Risk Understanding
Structured Risk Understanding
Structured Risk Understanding
Patient specific Insight beyond standard markers
Patient specific Insight beyond standard markers
Clearer Patient Communication
Clearer Patient Communication
Clearer Patient Communication
Translate complexity into meaningful discussion
Translate complexity into meaningful discussion
Preventive Differentiation
Preventive Differentiation
Preventive Differentiation
Offer a more advanced care model within your practice
Offer a more advanced care model within your practice
Start with a focused pilot
No long-term commitment required. See what Vizzhy reveals on your own patients before making any infrastructure decisions.
No long-term commitment required. See what Vizzhy reveals on your own patients before making any infrastructure decisions.
1
1
Select 10-25 cardiology patients
Select 10-25 cardiology patients
Post-stent, recurrent blockage, residual inflammation, unexplained progression - patients where your current approach has unanswered questions.
Post-stent, recurrent blockage, residual inflammation, unexplained progression - patients where your current approach has unanswered questions.
2
2
Collect samples and clinical data
Collect samples and clinical data
Blood draw, stool sample, saliva. Combined with existing imaging and labs. No EMR integration required.
Blood draw, stool sample, saliva. Combined with existing imaging and labs. No EMR integration required.
3
3
Vizzhy computes the BioTwin
Vizzhy computes the BioTwin
Multi-Omics analysis in certified labs. Cross-layer terrain computation. Full biological model generated per patient.
Multi-Omics analysis in certified labs. Cross-layer terrain computation. Full biological model generated per patient.
4
4
Joint physician review
Joint physician review
Your cardiologists review findings in the clinical intelligence interface. Side-by-side what standard care saw vs what Vizzhy revealed.
Your cardiologists review findings in the clinical intelligence interface. Side-by-side what standard care saw vs what Vizzhy revealed.
5
5
Evaluate and Decide
Evaluate and Decide
Did the BioTwin change the clinical picture? Did it reveal mechanisms your team would have not found? You decide the next step.
Did the BioTwin change the clinical picture? Did it reveal mechanisms your team would have not found? You decide the next step.
Every patient deserves care
based on their actual biology
Every patient deserves care
based on their actual biology
Every patient deserves care
based on their actual biology
Start with a small pilot on your own patients. See what changes. Then scale with confidence
Start with a small pilot on your own patients. See what changes. Then scale with confidence
Start with a small pilot on your own patients. See what changes. Then scale with confidence
Austin, TX - Now expanding to India and beyond
Austin, TX - Now expanding to India and beyond
Austin, TX - Now expanding to India and beyond
Start with a focused pilot
No long-term commitment required. See what Vizzhy reveals on your own patients before making any infrastructure decisions.
1
Select 10-25 cardiology patients
Post-stent, recurrent blockage, residual inflammation, unexplained progression - patients where your current approach has unanswered questions.
2
Collect samples and clinical data
Blood draw, stool sample, saliva. Combined with existing imaging and labs. No EMR integration required.
3
Vizzhy computes the BioTwin
Multi-Omics analysis in certified labs. Cross-layer terrain computation. Full biological model generated per patient.
4
Joint physician review
Your cardiologists review findings in the clinical intelligence interface. Side-by-side what standard care saw vs what Vizzhy revealed.
5
Evaluate and Decide
Did the BioTwin change the clinical picture? Did it reveal mechanisms your team would have not found? You decide the next step.